terbinafine (lamisil) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Terbinafine (brand name Lamisil, Terbisil, Terboderm and others) is an antifungal medication used to treat ringworm and fungal nail infections. Terbinafine inhibits ergosterol synthesis by inhibiting squalene epoxidase, an enzyme that is part of the fungal cell membrane synthesis pathway. Because terbinafine prevents the conversion of squalene to lanosterol, ergosterol cannot be synthesized. This is thought to change cell membrane permeability, causing fungal cell lysis. Many side effects and adverse drug reactions have been reported with oral terbinafine hydrochloride possibly due to its extensive biodistribution and the often extended durations involved in antifungal treatment (longer than two months).   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral, Topical
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.3491 - $11.4124
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

athlete's foot | da 5505 | (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalene methanamine | (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine | (e)-n-(6,6-dimethyl-2-heptenynyl)-n-methyl-1-naphthalenementhamin hydrochloride | lamisil | lamisil at | lamisil once | mob015 | p-3058 | sf 86-327 | sf-86327 | sf-86-327 | tdt067 | tdt-067 | terbinafina | terbinafine | terbinafine hcl | terbinafine hydrochloride | terbinafine, (z)-isomer | terbinafinum | terbinol

Organizations (58)

Research & Development (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (1)


 

Onychomycosis (approved 1998)

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Axial Spondyloarthritis (Early Phase 1)

Colitis, Ulcerative (Phase 2)

Crohn Disease (Phase 2)

Dermatomycoses (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Fasting (Phase 1)

Healthy Volunteers (Phase 1)

Inflammatory Bowel Diseases (Phase 2)

Intestinal Diseases (Early Phase 1)

Mycoses (Phase 2)

Neoplasms (Phase 2)

Onychomycosis (Phase 4)

Platelet-Rich Plasma (Phase 3)

Psoriasis (Early Phase 1)

Spondylarthropathies (Early Phase 1)

Spondylitis, Ankylosing (Early Phase 1)

Tinea (Phase 2)

Tinea Capitis (Phase 3)

Tinea Pedis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial Organizations: 42

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue